These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21128694)

  • 21. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Senek M; Nielsen EI; Nyholm D
    Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 24. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
    Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
    Kuoppamäki M; Korpela K; Marttila R; Kaasinen V; Hartikainen P; Lyytinen J; Kaakkola S; Hänninen J; Löyttyniemi E; Kailajärvi M; Ruokoniemi P; Ellmén J
    Eur J Clin Pharmacol; 2009 May; 65(5):443-55. PubMed ID: 19229530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
    Silver DE
    Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
    Nyholm D; Ehrnebo M; Lewander T; Trolin CG; Bäckström T; Panagiotidis G; Spira J; Nyström C; Aquilonius SM
    Acta Neurol Scand; 2013 Feb; 127(2):124-32. PubMed ID: 22762460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
    Novelli A; Di Vico IA; Terenzi F; Sorbi S; Ramat S
    Parkinsonism Relat Disord; 2019 Jul; 64():352-353. PubMed ID: 31101554
    [No Abstract]   [Full Text] [Related]  

  • 31. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA
    Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime.
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2020 Dec; 21(18):2265-2278. PubMed ID: 32808807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
    Myllylä V; Haapaniemi T; Kaakkola S; Kinnunen E; Hartikainen P; Nuutinen J; Rissanen A; Kuopio AM; Jolma T; Satomaa O; Heikkinen H
    Acta Neurol Scand; 2006 Sep; 114(3):181-6. PubMed ID: 16911346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
    Nissinen H; Kuoppamäki M; Leinonen M; Schapira AH
    Eur J Neurol; 2009 Dec; 16(12):1305-11. PubMed ID: 19570145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
    Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
    J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.